{
    "nctId": "NCT02910050",
    "briefTitle": "Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of the Efficacy and Tolerability of Bicalutamide Plus Aromatase Inhibitors in Estrogen Receptor(+)/Androgen Receptor(+)/HER2(-) Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 58,
    "primaryOutcomeMeasure": "clinical benefit rate\uff08CBR\uff09",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically confirmed estrogen receptor positive, androgen positive and HER2 negative breast cancer\n* Metastatic or unresectable locally advanced disease\n* Age over 18 years\n* Postmenopausal status \uff08continuous using luteinizing hormone releasing hormone(LHRH) analogue is available\uff09\n* Patient must have disease progression after treatment of an Aromatase inhibitor.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS)0-2\n* Life expectancy over 3 months.\n* Measurable disease according to RECIST version 1.1 or only bone metastasis\n* Adequate hematological, hepatic function.\n* Voluntarily signed and dated written informed consent prior to any study specific procedure.\n\nExclusion Criteria:\n\n* Patient with life-threatening visceral metastasis, such as extensive liver metastasis, brain or meningeal metastasis\n* Concomitant diseases/conditions that is not controllable, and Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.\n* History of other primary malignancy\n* Resistant to steroidal or nonsteroidal aromatase Inhibitor",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}